Search the Newsreel

Advanced Enzyme Technologies Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Advanced Enzyme Approves Buyback At ₹500 Per Share Amid Q1 Profit Of ₹37.1 Crore

ADVENZYMES: Q1 FY27 saw profit growth, a ₹697M buyback, and strategic investments in subsidiaries

Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO

Assenagon Asset Management S.A. significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4,578.9% in the second quarter, now holding 997,643 shares valued at $78.1 million. This increase follows Halozyme's strong second-quarter results, which exceeded analyst expectations with adjusted EPS of $2.28 and …

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was upgraded to a "strong-buy" rating by Wall Street Zen following impressive quarterly results where EPS and revenue significantly beat estimates. The company also raised its 2026 guidance, driven by strong royalty growth and new ENHANZE and Hypercon agreements. Despite some …

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance. …

Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...

This article first appeared on GuruFocus. Total Revenue: Increased 48% year-over-year to $481 million. Royalty Revenue: Record growth of 50% year-over-year to $308 million. Adjusted EBITDA: Increased 46% to $328.8 million, with a margin of more than 65%. Net Income: Increased 39% to $229.9 …

Zymeworks (ZYME) Stock Rich Valuation Meets Widening Losses

Zymeworks (NASDAQ:ZYME) Issues Earnings Results, Misses Expectations By $0.05 EPS

HALO Surges As Halozyme Hikes 2026 EPS And Revenue Outlook

Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth. Continue Reading

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

FUL vs. NVZMY: Which Stock Is the Better Value Option?

Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We …

Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike

Halozyme Therapeutics (HALO) surged by 19.44% after reporting Q2 earnings that significantly beat expectations, with non-GAAP EPS at $2.28 and revenue at $481M. The company also raised its 2026 non-GAAP EPS and revenue guidance above Street estimates, driven by strong royalty growth and new …

Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners

Leerink Partners has upgraded Halozyme Therapeutics (NASDAQ:HALO) from "market perform" to "outperform," setting a $110 price target. This upgrade follows Halozyme's strong quarterly results, with revenue up 47.7% year-over-year and EPS significantly beating estimates, leading management to raise its fiscal 2026 outlook. The company …

HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83

Leerink Partners has upgraded Halozyme Therapeutics, Inc. (HALO.O) from Market Perform to Outperform. The firm also increased its target price for Halozyme Therapeutics to $110, up from the previous $83. This suggests a more positive outlook on the company's stock performance.

Halozyme Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-08-07

Halozyme Therapeutics, Inc. (HALO) has published its Q2 2026 earnings call presentation, reporting significant financial beats. The company's EPS of $2.28 surpassed estimates by $0.46, and revenue reached $481.00M, exceeding expectations by $78.72M and showing a 47.67% year-over-year increase. This presentation was released in …

HALOZYME THERAPEUTICS, INC. 2026: Revenue $481M, EPS $1.9— 10-Q Summary

HALOZYME THERAPEUTICS, INC. reported strong financial results for the 2026 quarter, with revenue reaching $481 million and diluted EPS of $1.9. This growth was primarily driven by increased royalties, particularly from products like DARZALEX SC and VYVGART Hytrulo, and significant growth in bulk rHuPH20 …

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Halozyme Therapeutics (HALO) reported revenue of $481 million, up 47.7% over the same period last year. EPS came in at $2.28, compared to $1.54 in the year-ago quarter. The reported revenue represents a surprise of +17.44% over the …

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) reported Q2 earnings of $2.28 per share and revenues of $481 million, both exceeding Zacks Consensus Estimates. The company has consistently surpassed revenue estimates and its shares have outperformed the S&P 500 this year, though its Zacks Rank is currently "Hold" …

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 47.7% year on year to $481 million. The company's full-year …

HALOZYME THERAPEUTICS ($HALO) Releases Q2 2026 Earnings, Stock Rises

Halozyme Therapeutics (NASDAQ: HALO) posts $481M Q2 2026 revenue

Halozyme Therapeutics (NASDAQ: HALO) reported total revenues of $481 million for Q2 2026 and $857.7 million for the first half of 2026, alongside a quarterly net income of $230 million. The biopharmaceutical company, which specializes in drug-delivery technologies like ENHANZE and Hypercon, saw significant …

Earnings Flash (HALO) Halozyme Therapeutics, Inc. Reports Q2 Revenue $481.0M, vs. FactSet Est of $402.3M

Halozyme Therapeutics, Inc. (HALO) reported robust Q2 revenue of $481.0 million, significantly exceeding FactSet's estimate of $402.3 million. The biopharmaceutical company also updated its 2026 adjusted EPS guidance to a range of $8.65-$9.00, surpassing the FactSet estimate of $7.94, and raised its 2026 revenue …

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme Therapeutics, Inc. reported record second-quarter 2026 financial results, exceeding estimates and subsequently raising its full-year 2026 financial guidance. The company saw a 48% year-over-year increase in total revenue to $481 million, with royalty revenue growing 50% to $308 million, driven by the strong …

Halozyme earnings up next: Can royalty growth hit $1B target?

Halozyme Therapeutics Inc. is reporting second-quarter earnings, with investors keenly watching its partnership momentum and progress toward a $1 billion ENHANZE royalty revenue target. The company has shown strong growth and secured multiple licensing deals, contributing to its stock trading near 52-week highs. Investors …

Halozyme Therapeutics, Inc. Revenue Breakdown – LSX:A0DLHS

Halozyme Therapeutics, Inc. generated 1.19 billion EUR in revenue last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. This revenue marks an increase from 980.78 million EUR in the previous year. The United States was the largest contributor, …

Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Expectations By $0.49 EPS

Zymeworks (Nasdaq: ZYME) details Q2 loss, Theravance deal and PDUFA

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings

Halozyme Therapeutics (NASDAQ:HALO) is set to announce its Q2 earnings this Thursday. The company exceeded revenue expectations last quarter and analysts anticipate 24.1% year-on-year revenue growth for the upcoming report. Peers Biogen and Amgen have already reported strong Q2 results, with the therapeutics segment …

What Is the HALO Trade? Earnings, Not Assets, Will Decide the Next Winners

Advanced Enzyme Technologies Q4 Results: Earnings call scheduled for Aug 12

Halozyme Therapeutics Inc (HALO) - Tradingkey Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Halozyme Therapeutics Inc (HALO), highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis notes significant institutional ownership and a "Buy" rating from analysts with an average target price of …

Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis

Halozyme Therapeutics Inc (HALO) currently holds a financial score of 8.39, placing it 51st out of 155 companies in the Pharmaceuticals industry. While its overall financial status is deemed weak, its operating efficiency is high. The company recently reported a 42.23% year-over-year increase in …